Respiratory System
INTRODUCTION
Respiratory diseases rank among the most prevalent conditions globally, encompassing chronic obstructive pulmonary disease (COPD), bronchial asthma, and pneumonia. These disorders not only impair patients' respiratory function but may also lead to severe complications.
Boji Pharmaceuticals has managed numerous clinical trial projects for respiratory diseases including pulmonary infections, IPF, chronic refractory cough, COPD, and asthma. The company possesses extensive resources of respiratory specialists and maintains close collaborative relationships with the Guangzhou Institute of Respiratory Diseases.
Clinical Research Project Experience
- Chronic bronchitis
- Emphysema
- Allergic asthma
- Exercise-induced asthma
- Pneumonia
PROJECT EXPERIENCE

Assisted in the successful approval and market launch of Cefoperazone Sodium and Azobate Sodium for Injection (6:1)
On April 20, 2021, Xiangbei Wilmann Pharmaceutical Co., Ltd.'s Class 2 chemical new drug—Cefoperazone Sodium and Azobate Sodium for Injection (6:1)—received marketing approval from the National Medical Products Administration. This drug is a nationally significant innovative original drug jointly developed by China Pharmaceutical University and Xiangbei Wilmann. It is a novel compound formulation (registration category 1.5) not previously marketed domestically or internationally.
博济医药凭借丰富的经验和专业的团队,为该项目的临床试验提供了科学、严谨的管理服务,确保试验的顺利进行。
博济医药凭借丰富的经验和专业的团队,为该项目的临床试验提供了科学、严谨的管理服务,确保试验的顺利进行。